{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:24:07Z","timestamp":1783347847527,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Eugene Frenkel Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with social barriers have poor cancer outcomes. The combined relationship of cancer survival with guideline concordance, time to treatment, and social vulnerability has not been studied. Our objective was to determine whether optimal care is associated with survival and whether this relationship differs with social vulnerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients diagnosed with localized colon cancer, non-small-cell lung cancer (NSCLC), or pancreatic cancer from 2006 to 2016 and followed until 2021 were identified from California and Texas Cancer Registries and analyzed with the census-tract level Social Vulnerability Index. Optimal care (guideline-concordant treatment initiated within 60 days of diagnosis) was used to create an interaction variable by combining it with the Social Vulnerability Index. A multivariable Cox proportional hazards model was used for survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 100,294 patients, 68.7% of those with colon cancer, 22.6% of those with pancreatic cancer, and 70.6% of those with NSCLC received optimal care. Cox models showed that patients who received optimal care had the lowest hazard ratios (HRs) for death compared with those who received least optimal care: colon cancer, HR 0.45 (95% confidence interval [CI] 0.36\u20130.57), NSCLC, HR 0.35 (95% CI 0.32\u20130.38), pancreatic cancer, HR 0.46 (95% CI 0.39\u20130.54). On interaction analysis, for patients with colon cancer or NSCLC who received optimal care, the risk of death was higher for patients who lived in the most vulnerable neighborhoods than for those who did not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Care that is both guideline concordant and timely is associated with the highest overall survival for localized cancer. However, this association is reduced for patients with colon cancer or NSCLC residing in the most vulnerable neighborhoods.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19760-5","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T19:50:48Z","timestamp":1779047448000},"page":"7386-7395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined Association of Time to Treatment, Guideline Concordance, and Neighborhood Vulnerability with Localized Colon Cancer, Non-small-cell Lung Cancer, and Pancreatic Cancer Survival"],"prefix":"10.1245","volume":"33","author":[{"given":"Muhammad Sohaib","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert Z.","family":"Murimwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Zamarripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Herbert J.","family":"Zeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio M.","family":"Polanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"issue":"1","key":"19760_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"19760_CR2","doi-asserted-by":"crossref","unstructured":"Braveman P. The social determinants of health and health disparities. Oxford University Press; 2023: vii.","DOI":"10.1093\/oso\/9780190624118.001.0001"},{"key":"19760_CR3","unstructured":"National Cancer Plan. https:\/\/nationalcancerplan.cancer.gov\/. Accessed 7 Jan 2024."},{"issue":"12","key":"19760_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.30072","volume":"3","author":"EB Cone","year":"2020","unstructured":"Cone EB, Marchese M, Paciotti M, et al. Assessment of time-to-treatment initiation and survival in a cohort of patients with common cancers. JAMA Netw Open. 2020;3(12):e2030072. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.30072.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"19760_CR5","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/j.cllc.2020.09.004","volume":"22","author":"TR Cushman","year":"2021","unstructured":"Cushman TR, Jones B, Akhavan D, et al. The effects of time to treatment initiation for patients with non-small-cell lung cancer in the United States. Clin Lung Cancer. 2021;22(1):e84\u201397. https:\/\/doi.org\/10.1016\/j.cllc.2020.09.004.","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"19760_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213209","volume":"14","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Tullio K, Elson P, et al. Time to initial cancer treatment in the United States and association with survival over time: an observational study. PLoS One. 2019;14(3):e0213209. https:\/\/doi.org\/10.1371\/journal.pone.0213209.","journal-title":"PLoS One"},{"key":"19760_CR7","doi-asserted-by":"crossref","unstructured":"Levit L, Balogh E, Nass S, Ganz PA, editors. Delivering high-quality cancer care: charting a new course for a system in crisis. Washington (DC): National Academies Press (US); 2013.","DOI":"10.17226\/18359"},{"issue":"4","key":"19760_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"key":"19760_CR9","unstructured":"Texas Cancer Registry. https:\/\/www.dshs.texas.gov\/texas-cancer-registry"},{"issue":"1","key":"19760_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2202\/1547-7355.1792","volume":"8","author":"BE Flanagan","year":"2011","unstructured":"Flanagan BE, Gregory EW, Hallisey EJ, Heitgerd JL, Lewis B. A Social vulnerability index for disaster management. J Homeland Secur Emerg Manag. 2011;8(1):3. https:\/\/doi.org\/10.2202\/1547-7355.1792.","journal-title":"J Homeland Secur Emerg Manag"},{"issue":"1","key":"19760_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/2137284","volume":"36","author":"RM Andersen","year":"1995","unstructured":"Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1\u201310.","journal-title":"J Health Soc Behav"},{"issue":"Suppl 1","key":"19760_CR12","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1093\/geront\/gnz033","volume":"59","author":"RD Tucker-Seeley","year":"2019","unstructured":"Tucker-Seeley RD, Thorpe RJ. Material-psychosocial-behavioral aspects of financial hardship: a conceptual model for cancer prevention. Gerontologist. 2019;59(Suppl 1):S88\u201393. https:\/\/doi.org\/10.1093\/geront\/gnz033.","journal-title":"Gerontologist"},{"issue":"9","key":"19760_CR13","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2010.0073","volume":"8","author":"MA Tempero","year":"2010","unstructured":"Tempero MA, Arnoletti JP, Behrman S, et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010;8(9):972\u20131017. https:\/\/doi.org\/10.6004\/jnccn.2010.0073.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"19760_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.6004\/jnccn.2012.0073","volume":"10","author":"MA Tempero","year":"2012","unstructured":"Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012;10(6):703\u201313. https:\/\/doi.org\/10.6004\/jnccn.2012.0073.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"19760_CR15","doi-asserted-by":"publisher","first-page":"778","DOI":"10.6004\/jnccn.2009.0056","volume":"7","author":"PF Engstrom","year":"2009","unstructured":"Engstrom PF, Arnoletti JP, Benson AB 3rd, et al. NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw. 2009;7(8):778\u2013831. https:\/\/doi.org\/10.6004\/jnccn.2009.0056.","journal-title":"J Natl Compr Canc Netw"},{"key":"19760_CR16","doi-asserted-by":"publisher","first-page":"1422475","DOI":"10.3389\/fonc.2024.1422475","volume":"14","author":"A Mehta","year":"2024","unstructured":"Mehta A, Jeon WJ, Nagaraj G. Association of US county-level social vulnerability index with breast, colorectal, and lung cancer screening, incidence, and mortality rates across US counties. Front Oncol. 2024;14:1422475. https:\/\/doi.org\/10.3389\/fonc.2024.1422475.","journal-title":"Front Oncol"},{"issue":"6","key":"19760_CR17","doi-asserted-by":"publisher","first-page":"e904","DOI":"10.1200\/OP.22.00779","volume":"19","author":"R Sheni","year":"2023","unstructured":"Sheni R, Qin J, Viswanathan S, Castellucci E, Kalnicki S, Mehta V. Predictive factors for cancer treatment delay in a racially diverse and socioeconomically disadvantaged urban population. JCO Oncol Pract. 2023;19(6):e904\u201315. https:\/\/doi.org\/10.1200\/OP.22.00779.","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"19760_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1377\/hlthaff.2021.01394","volume":"41","author":"PA Braveman","year":"2022","unstructured":"Braveman PA, Arkin E, Proctor D, Kauh T, Holm N. Systemic and structural racism: definitions, examples, health damages and approaches to dismantling. Health Aff (Millwood). 2022;41(2):171\u20138. https:\/\/doi.org\/10.1377\/hlthaff.2021.01394.","journal-title":"Health Aff (Millwood)"},{"issue":"9","key":"19760_CR19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1200\/OP.22.00122","volume":"18","author":"AN Wercholuk","year":"2022","unstructured":"Wercholuk AN, Parikh AA, Snyder RA. The road less traveled: transportation barriers to cancer care delivery in the rural patient population. JCO Oncol Pract. 2022;18(9):652\u201362. https:\/\/doi.org\/10.1200\/OP.22.00122.","journal-title":"JCO Oncol Pract"},{"issue":"16","key":"19760_CR20","doi-asserted-by":"publisher","first-page":"17356","DOI":"10.1002\/cam4.6351","volume":"12","author":"MD Thomson","year":"2023","unstructured":"Thomson MD, Van Houtven CH, Xu R, Siminoff LA. The many \u201ccosts\u201d of transportation: examining what cancer caregivers experience as transportation obstacles. Cancer Med. 2023;12(16):17356\u201364. https:\/\/doi.org\/10.1002\/cam4.6351.","journal-title":"Cancer Med"},{"issue":"3","key":"19760_CR21","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1007\/s11357-025-01648-z","volume":"47","author":"Z Ungvari","year":"2025","unstructured":"Ungvari Z, Fekete M, Fekete JT, et al. Treatment delay significantly increases mortality in colorectal cancer: a meta-analysis. Geroscience. 2025;47(3):5337\u201353. https:\/\/doi.org\/10.1007\/s11357-025-01648-z.","journal-title":"Geroscience"},{"issue":"9","key":"19760_CR22","doi-asserted-by":"publisher","first-page":"e835","DOI":"10.1093\/oncolo\/oyad176","volume":"28","author":"KY Chen","year":"2023","unstructured":"Chen KY, Blackford AL, Sedhom R, Gupta A, Hussaini SMQ. Local social vulnerability as a predictor for cancer-related mortality among US Counties. Oncologist. 2023;28(9):e835\u20138. https:\/\/doi.org\/10.1093\/oncolo\/oyad176.","journal-title":"Oncologist"},{"key":"19760_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006282","author":"J Meier","year":"2024","unstructured":"Meier J, Murimwa G, Nehrubabu M, et al. Defining the Role of social vulnerability in treatment and survival in localized colon cancer: a retrospective cohort study. Ann Surg. 2024. https:\/\/doi.org\/10.1097\/SLA.0000000000006282.","journal-title":"Ann Surg"},{"issue":"2","key":"19760_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/XCS.0000000000001193","volume":"240","author":"K Chan","year":"2025","unstructured":"Chan K, Palis BE, Cotler JH, et al. Social vulnerability and receipt of guideline-concordant care among patients with colorectal cancer. J Am Coll Surg. 2025;240(2):167\u201378. https:\/\/doi.org\/10.1097\/XCS.0000000000001193.","journal-title":"J Am Coll Surg"},{"key":"19760_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107452","volume":"188","author":"CM Stuart","year":"2024","unstructured":"Stuart CM, Dyas AR, Bronsert MR, et al. The effect of social vulnerability on initial stage and treatment for non-small cell lung cancer. Lung Cancer. 2024;188:107452. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107452.","journal-title":"Lung Cancer"},{"issue":"11","key":"19760_CR26","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1245\/s10434-021-09911-1","volume":"28","author":"RA Azap","year":"2021","unstructured":"Azap RA, Diaz A, Hyer JM, et al. Impact of race\/ethnicity and county-level vulnerability on receipt of surgery among older medicare beneficiaries with the diagnosis of early pancreatic cancer. Ann Surg Oncol. 2021;28(11):6309\u201316. https:\/\/doi.org\/10.1245\/s10434-021-09911-1.","journal-title":"Ann Surg Oncol"},{"key":"19760_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-3-642-83293-2_12","volume":"110","author":"JA Wils","year":"1988","unstructured":"Wils JA. Treatment of pancreatic carcinoma: therapeutic nihilism? Recent Results Cancer Res. 1988;110:87\u201394. https:\/\/doi.org\/10.1007\/978-3-642-83293-2_12.","journal-title":"Recent Results Cancer Res"},{"issue":"2","key":"19760_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/00006676-198703000-00017","volume":"2","author":"HOJ Douglass","year":"1987","unstructured":"Douglass HOJ. Pancreatic Cancer: Nihilism is Obsolete! Pancreas. 1987;2(2):230\u20132.","journal-title":"Pancreas"},{"issue":"4","key":"19760_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/jso.27357","volume":"128","author":"GZ Murimwa","year":"2023","unstructured":"Murimwa GZ, Karalis JD, Meier J, et al. Factors associated with failure to operate and its impact on survival in early-stage pancreatic cancer. J Surg Oncol. 2023;128(4):540\u20138. https:\/\/doi.org\/10.1002\/jso.27357.","journal-title":"J Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19760-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19760-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19760-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:40:38Z","timestamp":1783345238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19760-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["19760"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19760-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Zeh is on the scientific advisory board of Surgical Safety Technologies. Dr. Polanco is a consultant at Iota Bioscience, proctor for Intuitive Surgical, and consultant for Medtronics Inc. The other authors have no related conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}